The bioreactors market includes instruments used for mammalian, microbial, and cell culture growth in the biotechnology and pharmaceutical industry. Single-use bioreactors provide advantages like lower risk of contamination, reduced cleaning and sterilization efforts, and easier scale-up. They find wide application in production of monoclonal antibodies, vaccines, and gene therapies.
The global bioreactors market is estimated to be valued at US$ 20.5 Bn in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing adoption of single-use bioreactors has been a key trend driving growth in the bioreactors market. Several biopharmaceutical companies have shifted focus towards single-use technologies to streamline manufacturing processes. They help eliminate the need for capital-intensive stainless-steel equipment and facilitate small-volume production more cost-effectively. With the growing demand for personalized and flexible manufacturing in the biologics industry, single-use bioreactors allow producing multiple products simultaneously in smaller batches with ease. Their widespread acceptance is expected to boost revenue generation in the global bioreactors market during the forecast period.
Segment Analysis
The global bioreactors market growth is dominated by single-use bioreactors sub-segment which occupied over 50% of the total market share in 2022. Single-use bioreactors are preferred by most biopharmaceutical manufacturers owing to their advantages over stainless steel bioreactors such as reduced validation efforts and lower capital costs. They minimize the costs associated with cleaning and sterilization between production batches.
Key Takeaways
The global bioreactors market is expected to witness high growth over the forecast period of 2023 to 2030. The global bioreactors market is estimated to be valued at US$ 20.5 Bn in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030.
Regional analysis
North America held the largest market share of over 40% in 2022. This can be attributed to presence of large biopharmaceutical industry in countries like the US and rising demand for biotherapeutics. However, Asia Pacific is anticipated to grow at the highest CAGR during the forecast period supported by generous government funding for research activities and rising adoption of single-use bioreactors by emerging biosimilar manufacturers in countries like China, India and South Korea.
Key players
Key players operating in the bioreactors market are Pfizer, Inc., Novartis AG, Kite Pharma, Inc., Bluebird bio, Inc., Boehringer Ingelheim International GmbH, Merck & Co., CELGENE CORPORATION. Pfizer is one of the leading players offering single-use and steel bioreactors for manufacturing various biotherapeutic products. Novartis AG provides fluid management systems and single-use bioreactors for cell and gene therapy applications.
Explore Our More Blogs Here: https://www.newsstatix.com/bioreactors-market-share-and-opportunity-analysis/
